Non-radiographic axial spondyloarthritis (AXSPA) Program in Pharmaceutical Benefits Scheme (PBS) 012-18112216
Expand allThis document outlines details of PBS-subsidised biological medicine for patients with non-radiographic axial spondyloarthritis (AXSPA).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Non-radiographic axial spondyloarthritis (AXSPA) quick reference
Non-radiographic axial spondyloarthritis (AXSPA) quick reference
Table 1
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB255 form |
Written Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib |
No |
OPA |
Must be treated by a:
|
Yes – immediate or delayed assessment (delayed if any free text option used) |
|
Grandfather PB353 form |
Written Electronic S85: bimekizumab |
No |
OPA |
Must be treated by a:
|
Yes – immediate or delayed assessment (delayed if any free text option used) |
|
Continuing |
Telephone Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib |
No |
OPA |
Must be treated by a:
|
Yes |
|
Change or:
|
Telephone Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib |
No |
OPA |
Must be treated by a:
|
Yes |
|
Balance of supply |
Telephone Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib |
No |
OPA |
Must be treated by a:
|
Yes |
Delayed assessment
Delayed assessment due to contraindication and/or intolerance to optimised AXSPA therapy.
Table 2 lists the details of what to check for the delayed assessment and common acronyms.
Common acronyms
- LFT - Liver function tests
- GI toxicity - Gastrointestinal
- N+V - Nausea and vomiting
Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of acronym used.